Campaigners are urgently calling on Health Secretary Wes Streeting to overturn the UK National Screening Committee's (UK NSC) draft recommendation against a routine, nationwide prostate cancer screening programme. They argue that the decision, which is due to be finalised this spring, is built upon "flawed modelling" that potentially inflates the risks and plays down the survival benefits of screening.
Prostate cancer represents a significant health crisis in the UK, being the most common cancer in men with over 63,000 new diagnoses and 12,000 deaths annually. Despite this massive public health burden, it stands alone as the only major cancer in the country without a national screening strategy, a lack that has drawn heavy criticism from various patient groups and clinicians.
The UK NSC provisionally concluded in November 2025 that the potential harms of mass screening—chiefly overdiagnosis and overtreatment linked to the traditional prostate-specific antigen (PSA) test—outweigh the benefits for the general male population. The primary concern is that the PSA test often detects slow-growing cancers that would never become life-threatening, leading to unnecessary biopsies, complications, and treatments. The NSC did, however, endorse a targeted programme for men with confirmed BRCA1 or BRCA2 gene variants, who face a higher inherent risk.
The focus of the new challenge, backed by groups like Prostate Cancer Research, is on the foundational evidence: the economic and health modelling from the Sheffield Centre for Health and Related Research. Critics allege this model contains critical errors that skew the risk-benefit analysis. Specifically, they claim the model underestimates the benefits by assuming a national programme wouldn't alter the behaviour of men already seeking opportunistic PSA tests. This, they argue, understates the number of early-stage cancers that a structured programme would detect and effectively treat in key age groups (50–70).
Furthermore, the model is criticised for not adequately accounting for potential NHS cost savings from diagnosing cancers earlier and for failing to address critical health inequalities. Black men and those from deprived areas face a higher risk of prostate cancer but have lower testing rates, a disparity that critics say the modelling neglects. A methodological review by the York Health Economics Consortium supported these concerns, describing the original assumptions, especially those about spontaneous PSA testing, as "incomplete and implausible."
Advocates assert that a structured, quality-controlled screening approach, utilising modern diagnostics, would standardise care, reduce regional disparities, and significantly improve survival rates. They also suggest that targeted screening for high-risk populations, such as Black men and those with a strong family history, could effectively address inequalities without overburdening the NHS. The future feasibility of screening is also boosted by technological advancements, including NHS pilots using AI-enhanced imaging to improve diagnostic speed and accuracy.
Health Secretary Wes Streeting has promised a "thorough examination" of the evidence before a final decision. The UK NSC is expected to publish its conclusive advice in March or early spring 2026. The Department of Health and Social Care remains firm that any national screening programme must be demonstrably cost-effective, ensuring the overall benefits of early detection convincingly outweigh the persistent risks associated with overdiagnosis and overtreatment.
